Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

News & Events

News & Events menu

Press Releases
Events

CSS to format presentations

October 2021 Corporate Presentation

October 2021 Corporate Presentation

lnk News

Press Releases

View All

October 1, 2021

Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

August 18, 2021

Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

August 5, 2021

Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress

lnk Past Events

Events

View Past Events

June 10, 2021 at 3:00 PM EDT

Goldman Sachs 42nd Annual Global Healthcare Conference

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2021 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter